Risk For Below Knee Amputations With Canagliflozin Vs Other Antihyperglycemic Agents | Latest News RSS feed

Risk For Below Knee Amputations With Canagliflozin Vs Other Antihyperglycemic Agents - Latest News


Risk for Below Knee Amputations With Canagliflozin vs Other Antihyperglycemic Agents

ORLANDO — A real-world analysis of individuals within the United States examined the association of sodium glucose co-transporter 2 inhibitors (SGLT2i) on below knee amputation in patients with type 2 ... read more

Real World Study Suggests Canagliflozin Does Not Increase Risk o - wistv.com - Columbia, South Carolina

"Canagliflozin (CANA) vs. Other Antihyperglycemic Agents on the Risk of Below-Knee Amputation (BKA) for Patients with T2DM-A Real-World Analysis of >700,000 U.S. Patients," presented today at the Amer... read more

Real World Study Suggests Canagliflozin Does Not Increase Risk of Below-Knee Amputation in People with Type 2 Diabetes

Risk of BKA and HHF in the overall ... p value Cal p value BKA CANA vs non-SGLT2i 111,332/ 53,125 445,367/ 256,646 60 481 0.75 (0.40-1.41) 0.25 0.30 295 1,308 1.01 (0.93-1.10) 0.71 0.51 CANA vs other ... read more

Looking for another news?


Johnson & Johnson : - No Increased Risk of Below-Knee Lower Extremity Amputations with INVOKANA Compared to Other Diabetes Medications

which found no increased risk of below-knee lower extremity (BKLE) amputation with INVOKANA (canagliflozin) compared to other sodium glucose cotransporter 2 inhibitors (SGLT2i) or non-SGLT2i anti-hype... read more


Boehringer Ingelheim Launches RE-VECTO Global Program to Capture Data on Praxbind® (idarucizumab) Usage in Clinical Practice

Aug. 15, 2016 /PRNewswire/ -- Boehringer Ingelheim today announces its global ... at 10:00 Real World Study Suggests Canagliflozin Does Not Increase Risk of Below-Knee Amputation in People with Type 2 ... read more

Pharmacovigilance Risk Assessment Committee (PRAC)

Risk Management Plans (RMPs) (Item 5 of the PRAC agenda) The RMP describes what is known and not known about the side effects of a medicine and states how these risks will be prevented or minimised in ... read more

Real-World Study of More than 700,000 People with Type 2 Diabete - KLTV.com - Tyler, Longview, Jacksonville |ETX News

However, an increased risk of BKLE amputation was seen with INVOKANA ® in the ... receptor agonist, or other anti-hyperglycemic agents (acarbose, bromocriptine, miglitol, nateglinide, and repaglinide) ... read more

Real World Study Suggests Canagliflozin Does Not Increase Risk of Below-Knee Amputation in People with Type 2 Diabetes

Risk of BKA and HHF in the overall ... p value Cal p value BKA CANA vs non-SGLT2i 111,332/ 53,125 445,367/ 256,646 60 481 0.75 (0.40-1.41) 0.25 0.30 295 1,308 1.01 (0.93-1.10) 0.71 0.51 CANA vs other ... read more

Johnson & Johnson : Janssen Pharmaceutical Companies - Real-World Study of More than 700,000 People with Type 2 Diabetes

which found no increased risk of below-knee lower extremity (BKLE) amputation with INVOKANA (canagliflozin) compared to other sodium glucose cotransporter 2 inhibitors (SGLT2i) or non-SGLT2i anti-hype... read more



FeedsRSS Created by. Full RSS Feed | Privacy Policy | Contact Us